Vivos Therapeutics (NASDAQ:VVOS) and Iradimed (NASDAQ:IRMD) Head to Head Review

Vivos Therapeutics (NASDAQ:VVOS) and Iradimed (NASDAQ:IRMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Earnings and Valuation

This table compares Vivos Therapeutics and Iradimed”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$13.80 million	0.62	-$13.58 million	($7.03)	-0.36
Iradimed	$65.56 million	9.74	$17.19 million	$1.46	34.53

Iradimed has higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Vivos Therapeutics has a beta of 7.72, meaning that its stock price is 672% more volatile than the S&P 500. Comparatively, Iradimed has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Institutional and Insider Ownership

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 92.3% of Iradimed shares are held by institutional investors. 9.6% of Vivos Therapeutics shares are held by company insiders. Comparatively, 37.1% of Iradimed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Vivos Therapeutics and Iradimed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-85.90%	-652.32%	-98.95%
Iradimed	26.83%	24.71%	20.86%

Analyst Ratings

This is a summary of recent ratings for Vivos Therapeutics and Iradimed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	0	0	1	0	3.00
Iradimed	0	0	3	0	3.00

Vivos Therapeutics currently has a consensus target price of $6.60, suggesting a potential upside of 160.87%. Iradimed has a consensus target price of $60.00, suggesting a potential upside of 19.02%. Given Vivos Therapeutics’ higher possible upside, equities research analysts clearly believe Vivos Therapeutics is more favorable than Iradimed.

Summary

Iradimed beats Vivos Therapeutics on 11 of the 13 factors compared between the two stocks.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.